Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Relay Therapeutics Inc
(NQ:
RLAY
)
7.200
+0.260 (+3.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
619,573
Open
7.030
Bid (Size)
6.420 (3)
Ask (Size)
7.310 (10)
Prev. Close
6.940
Today's Range
6.890 - 7.280
52wk Range
5.700 - 12.14
Shares Outstanding
121,613,181
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Expert Ratings For Relay Therapeutics
August 07, 2024
Via
Benzinga
RLAY Stock Earnings: Relay Therapeutics Beats EPS for Q2 2024
August 06, 2024
RLAY stock results show that Relay Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-39.27%
-39.27%
1 Month
-20.53%
-20.53%
3 Month
+6.35%
+6.35%
6 Month
-29.13%
-29.13%
1 Year
-29.89%
-29.89%
More News
Read More
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 06, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
July 30, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Expert Ratings For Relay Therapeutics
July 17, 2024
Via
Benzinga
Expert Ratings For Relay Therapeutics
June 07, 2024
Via
Benzinga
Key Takeaways From Relay Therapeutics Analyst Ratings
May 10, 2024
Via
Benzinga
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
Via
Talk Markets
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
July 24, 2024
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
June 10, 2024
Via
Talk Markets
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
June 06, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
June 05, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
Via
Talk Markets
Relay Therapeutics to Participate in Upcoming Investor Conferences
May 21, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
May 13, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
5 Of 7 AI Categories Rose, Slightly,Over Past Week
May 11, 2024
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 7 AI Categories Declined, On Average, The First Week Of May
May 05, 2024
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
Via
Talk Markets
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.